FDA Expands Abbott's CardioMEMS HF System Approval
The U.S. Food and Drug Administration (FDA) has expanded the indication for Abbott's CardioMEMS HF System. The new approval allows the device to be used for patients with earlier-stage heart failure.
Abbott Laboratories has received expanded FDA approval for its CardioMEMS HF System, broadening its use to patients experiencing earlier stages of heart failure.
The CardioMEMS HF System is a small, paperclip-sized implanted device that monitors pressure in the pulmonary artery, an indicator of worsening heart failure. The system wirelessly transmits this data to clinicians, enabling monitoring before patients develop symptoms.
With the new FDA indication, the device can now also be used for patients who have not been hospitalized for heart failure but have an elevated blood biomarker indicating stress on the heart. This allows for earlier intervention and management to reduce strain on the heart.
Abbott states that early detection is crucial for managing heart failure. While many cardiac conditions are symptom-based, the CardioMEMS HF System provides insight into disease progression by measuring pulmonary artery pressure. The system is now indicated for NYHA Class II or III patients who have been hospitalized in the past year or have elevated natriuretic peptides.